Enhanced Therapeutic Efficacy of a Novel Oncolytic Herpes Simplex Virus Type 2 Encoding an Antibody Against Programmed Cell Death 1
2019 · Molecular Therapy — Oncolytics · 32 citations
https://doi.org/10.1016/j.omto.2019.10.003
L
Lin Feng
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
103
Papers
2.4K
Citations
27
h-index
51
i10-index
Lin Feng is an academic researcher from Tianjin University of Science and Technology. The author has contributed to research in topics: RNA modifications and cancer & Cancer Immunotherapy and Biomarkers & Cancer-related molecular mechanisms research. The author has an h-index of 27, co-authored 88 publications.
ORCID: 0000-0003-0951-713XPapers by this author
worksoHSV2 Can Target Murine Colon Carcinoma by Altering the Immune Status of the Tumor Microenvironment and Inducing Antitumor Immunity
2020 · Molecular Therapy — Oncolytics · 28 citations
https://doi.org/10.1016/j.omto.2019.12.012
Neutrophil extracellular traps primed intercellular communication in cancer progression as a promising therapeutic target
2023 · Biomarker Research · 28 citations
https://doi.org/10.1186/s40364-023-00463-y
Over-expression of ANP32E is associated with poor prognosis of pancreatic cancer and promotes cell proliferation and migration through regulating β-catenin
2020 · BMC Cancer · 21 citations
https://doi.org/10.1186/s12885-020-07556-z
Decoding the colorectal cancer ecosystem emphasizes the cooperative role of cancer cells, TAMs and CAFsin tumor progression
2022 · Journal of Translational Medicine · 19 citations
https://doi.org/10.1186/s12967-022-03661-8
A network-based predictive gene-expression signature for adjuvant chemotherapy benefit in stage II colorectal cancer
2017 · BMC Cancer · 17 citations
https://doi.org/10.1186/s12885-017-3821-4
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat